0001209191-19-052836.txt : 20191009
0001209191-19-052836.hdr.sgml : 20191009
20191009171212
ACCESSION NUMBER: 0001209191-19-052836
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191008
FILED AS OF DATE: 20191009
DATE AS OF CHANGE: 20191009
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaughn James J
CENTRAL INDEX KEY: 0001649689
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 191144888
MAIL ADDRESS:
STREET 1: C/O GENOMIC HEALTH, INC.
STREET 2: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-10-08
0
0001131324
GENOMIC HEALTH INC
GHDX
0001649689
Vaughn James J
301 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
Chief Commercial Officer
Common Stock
2019-10-08
4
M
0
4500
33.21
A
20917
D
Common Stock
2019-10-08
4
S
0
4500
67.7501
D
16417
D
Employee Stock Option (right to buy) Holding
33.21
2019-10-08
4
M
0
4500
0.00
D
2028-01-31
Common Stock
4500
39707
D
Includes an aggregate of 11,281 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 11, 2019.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $67.46 to $68.29.
The option became exercisable as to 25% of the shares on January 31, 2019, and becomes exercisable as to 1/48th of the shares each full month thereafter.
/s/ Jason W. Radford, Attorney-in-fact
2019-10-09